Karyopharm Therapeutics Inc.
KPTI Real Time Price USDRecent trades of KPTI by members of U.S. Congress
No Congress Trading data for this ticker
Congress Trading Dashboard
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
---|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Recently reported changes by institutional investors
Quarterly net insider trading by KPTI's directors and management
Government lobbying spending instances
-
$40,000 Jan 21, 2020 Issue: Pharmacy
-
$60,000 Oct 21, 2019 Issue: Pharmacy
-
$60,000 Jul 22, 2019 Issue: Pharmacy
-
$60,000 Apr 22, 2019 Issue: Pharmacy
-
$60,000 Jan 23, 2019 Issue: Pharmacy
Estimated quarterly lobbying spending
No Corporate Lobbying data for this ticker
Corporate Lobbying DashboardNew patents grants
-
Patent Title: Nuclear transport modulators and uses thereof Apr. 02, 2024
-
Patent Title: Polymorphs of selinexor Nov. 07, 2023
-
Patent Title: Hydrazide containing nuclear transport modulators and uses thereof Oct. 17, 2023
-
Patent Title: Polymorphs of selinexor Sep. 12, 2023
-
Patent Title: Polymorphs of selinexor Sep. 05, 2023
-
Patent Title: Nuclear transport modulators and uses thereof Sep. 21, 2021
-
Patent Title: Polymorphs of selinexor Aug. 03, 2021
-
Patent Title: Hydrazide containing nuclear transport modulators and uses thereof Jun. 15, 2021
-
Patent Title: Substituted benzofuranyl and benzoxazolyl compounds and uses thereof May. 18, 2021
-
Patent Title: Multicyclic compounds and uses thereof Dec. 08, 2020
-
Patent Title: Hydrazide containing nuclear transport modulators and uses thereof Jan. 28, 2020
-
Patent Title: Nuclear transport modulators and uses thereof Jan. 07, 2020
-
Patent Title: Polymorphs of selinexor Dec. 31, 2019
-
Patent Title: Nuclear transport modulators and uses thereof Sep. 10, 2019
-
Patent Title: Substituted benzofuranyl and benzoxazolyl compounds and uses thereof Sep. 03, 2019
-
Patent Title: (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer Jul. 30, 2019
-
Patent Title: Methods of promoting wound healing using crm1 inhibitors Feb. 12, 2019
-
Patent Title: Hydrazide containing nuclear transport modulators and uses thereof Jan. 08, 2019
-
Patent Title: Multicyclic compounds and methods of using same Jun. 12, 2018
-
Patent Title: Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof Apr. 10, 2018
-
Patent Title: Nuclear transport modulators and uses thereof Jan. 09, 2018
-
Patent Title: Substituted benzofuranyl and benzoxazolyl compounds and uses thereof Jan. 02, 2018
-
Patent Title: Nuclear transport modulators and uses thereof Aug. 22, 2017
-
Patent Title: Hydrazide containing nuclear transport modulators and uses thereof Jul. 25, 2017
-
Patent Title: Nuclear transport modulators and uses thereof Mar. 07, 2017
-
Patent Title: Nuclear transport modulators and uses thereof Jan. 24, 2017
-
Patent Title: Nuclear transport modulators and uses thereof Aug. 30, 2016
-
Patent Title: Olefin containing nuclear transport modulators and uses thereof Apr. 05, 2016
-
Patent Title: Nuclear transport modulators and uses thereof Feb. 23, 2016
-
Patent Title: Hydrazide containing nuclear transport modulators and uses thereof Dec. 08, 2015
-
Patent Title: Nuclear transport modulators and uses thereof Aug. 04, 2015
-
Patent Title: Hydrazide containing nuclear transport modulators and uses thereof Jul. 14, 2015
-
Patent Title: Hydrazide containing nuclear transport modulators and uses thereof Apr. 07, 2015
-
Patent Title: Nuclear transport modulators and uses thereof Aug. 20, 2013
Federal grants, loans, and purchases
No Government Contracts for this ticker
Government Contracts DashboardEstimated quarterly amount awarded from public contracts
Number of mentions of KPTI in WallStreetBets Daily Discussion
Recent insights relating to KPTI
Recent picks made for KPTI stock on CNBC
ETFs with the largest estimated holdings in KPTI
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view KPTI Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.